Daytime carryover of triazolam and flurazepam in elderly insomniacs.
Daytime carryover of triazolam and flurazepam in elderly insomniacs.
复制标题
老年失眠症患者白天残留三唑仑和氟西泮。
作者：
Carskadon,MA;Seidel,WF;Greenblatt,DJ;Dement,WC
本文报告三唑仑（0.25mg）或泮（15 mg）治疗老年失眠症13例的疗效。受试者相当健康，能走动，并抱怨睡眠紊乱。通过夜间多导睡眠图排除了睡眠呼吸暂停综合征。连续5天评估睡眠、日间嗜睡[多次睡眠潜伏期测试（MSL T）和斯坦福大学嗜睡量表（SSS）]、表现和情绪[情绪状态量表（POMS）]。第1和第2晚给予安慰剂;第3-5晚给予活性药物。两组的睡眠时间均增加约1小时。Moglobin显示使用泮时嗜睡增加，使用三唑仑时嗜睡减少。在泮组中，MSPs评分与夜间睡眠参数无关，在三唑仑组中，MSPs评分与夜间睡眠参数相关，但不显著。使用泮可降低警惕性，而使用三唑仑则无变化。其他性能测试显示药物轻微改善或无变化。服用泮后情绪趋于改善，服用三唑仑后情绪无变化。这些研究结果表明，虽然这两种化合物改善老年失眠症患者的夜间睡眠，有显着的残留镇静与泮和改善白天警觉与三唑仑。这两种化合物对这些非睡眠呼吸暂停老年受试者的夜间呼吸都没有显着影响。
The effects of triazolam (0.25 mg) or flurazepam (15 mg) were evaluated in 13 elderly (ages 64-79) insomniacs. Subjects were reasonably healthy, ambulatory, and complained of disturbed sleep. Sleep apnea syndromes were ruled out by nocturnal polysomnogram. Sleep, daytime sleepiness [Multiple Sleep Latency Test (MSL T) and Stanford sleepiness scale (SSS)], performance, and mood [Profile of Mood States (POMS)] were assessed on five consecutive days. Placebo was given on nights 1 and 2; active medications were given on nights 3-5. Sleep time was increased by approximately 1 h in both groups. MSLT showed increased sleepiness with flurazepam and decreased sleepiness with triazolam. MSLT scores were unrelated to nocturnal sleep parameters in the flurazepam group and showed a pattern of correlation, though nonsignificant, in the triazolam group. Vigilance was impaired with flurazepam and unchanged with triazolam. Other performance tests showed slight improvement or no change with drugs. Mood tended to be improved after flurazepam ingestion and unchanged after triazolam. These findings suggest that, although both compounds improve nocturnal sleep in elderly insomniacs, there is significant residual sedation with flurazepam and improved daytime alertness with triazolam. Neither compound had a significant effect on nocturnal respiration in these non-sleep-apneic elderly subjects.